Advertisement
Advertisement
U.S. Markets close in 13 mins
Advertisement
Advertisement
Advertisement
Advertisement

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.4700-0.0100 (-0.29%)
As of 03:45PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.4800
Open3.4800
Bid3.4600 x 1000
Ask3.4700 x 800
Day's Range3.3800 - 3.5850
52 Week Range2.2300 - 6.3800
Volume79,679
Avg. Volume787,491
Market Cap153.326M
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor

    Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR. “Inhibition of the C5a/C5aR axis provides strong anti-inflammatory effects in a vari

  • GlobeNewswire

    InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events

    Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at sev

  • GlobeNewswire

    InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)

    Proof of concept established for potential of vilobelimab to reduce use of corticosteroids in AAV patients: vilobelimab demonstrated comparable efficacy to standard of careUse of vilobelimab instead of glucocorticoids led to a substantially lower observed glucocorticoid toxicityVilobelimab demonstrated a good safety and tolerability profile; vilobelimab only treatment arm had lowest number of reported treatment emergent adverse events JENA, Germany, Nov. 15, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V.

Advertisement
Advertisement